Key result
Mitoxantrone resulted in a 17% response rate compared to 30% for doxorubicin in patients with CMF-refractory breast cancer, which was not statistically different.
Why the study?
Does mitoxantrone improve response rates compared to doxorubicin in patients with breast cancer refractory to CMF?
Population
90 patients with breast cancer refractory to cyclophosphamide/fluorouracil/methotrexate (CMF)
Comparison
Mitoxantrone vs Doxorubicin
Design
RCT, Randomized in their treatment
Authors
Loading...
Comparable responses in small cohort do not guide agent selection; leaves open need for larger randomized trials.
RCT (n=90)
Does mitoxantrone improve response rates compared to doxorubicin in patients with breast cancer refractory to CMF?
Absolute Event Rate: 17% vs 30%
p-value: p=not statistically different
Mitoxantrone offers comparable efficacy to doxorubicin in CMF-refractory breast cancer with fewer nonhematologic side effects, though both agents carry a risk of cardiotoxicity.
Neidhart et al. (1986) conducted an RCT in breast cancer (n=90). mitoxantrone vs. doxorubicin was evaluated on response rate (p=not statistically different). Mitoxantrone resulted in a 17% response rate compared to 30% for doxorubicin in patients with CMF-refractory breast cancer, which was not statistically different.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: